Quantitative SSTR-PET/CT: A Po-tential Tool for Predicting Evero-limus Response in NET Patients
Abstract
Background. This study aimed to assess 68Ga-DOTA-TATE (-TOC) PET/CT quantitative parameters in monitoring and predicting everolimus response in neuroendocrine tumor (NET) patients with hepatic metastases (NELM).
Patients and methods. / Materials and methods. This retrospective analysis included 29 patients with 62 target lesions undergoing everolimus treatment and pre-therapy, and follow-up 68Ga-DOTA-TATE (-TOC) PET/CT scans. Response evaluation utilized progression-free survival (PFS) categorized as responders (R; PFS > 6 months) and non-responders (NR; PFS ≤ 6 months). Lesion size and density, along with SUV in target lesions, liver, and spleen were assessed. Tumor-to-spleen (T/S) and tumor-to-liver (T/L) ratios were calculated.
Results. PET/CT scans were acquired 19 days (IQ 69 days) pre-treatment and 127 days (IQR 74 days) post-starting everolimus. The overall median PFS was 264 days (95% CI: 134 – 394 days). R exhibited significant decreases in Tmax/Lmax and Tmean/Lmax ratios compared to NR (p=0.01). In univariate Cox regression, Tmean/Lmax ratio was the sole prognostic parameter associated with PFS (HR 0.5, 95% CI 0.28-0.92, p=0.03). Percentage changes in T/L and T/S ratios were significant predictors of PFS, with the highest AUC for the percentage change of Tmean/Lmax (AUC=0.73). An optimal threshold of < 2.5% identified patients with longer PFS (p=0.003). No other imaging or clinical parameters were predictive of PFS.
Conclusions. This study highlights the potential of quantitative SSTR-PET/CT in predicting and monitoring everolimus response in NET patients. Liver metastasis-to-liver parenchyma ratios outperformed size-based criteria, and Tmean/Lmax ratio may serve as a prognostic marker for PFS, warranting larger cohort investigation.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Homeira Karim, Michael Winkelmann, Freba Grawe, Friederike Völter, Christoph Auernhammer, Johannes Rübenthaler, Jens Ricke, Maria Ingenerf, Christine Schmid-Tannwald
This work is licensed under a Creative Commons Attribution 4.0 International License.
License to Publish
Please read the terms of this agreement, print, initial page 1, sign page 3, scan and send the document as one file attached to an e-mail to gsersa@onko-i.si